RecruitingNCT06045923
Virologic and Immunologic Characteristics of Severe Mpox in Persons With Advanced HIV
Sponsor
Centers for Disease Control and Prevention
Enrollment
100 participants
Start Date
Mar 17, 2023
Study Type
OBSERVATIONAL
Conditions
Summary
The purpose of this study is to examine the extent of mpox viral spread and immunologic markers in people with advanced HIV. Study findings will enhance knowledge of mpox pathogenesis in severely immunocompromised people, which can inform treatment and prevention of severe illness and deaths associated with mpox in people with advanced HIV.
Eligibility
Min Age: 18 Years
Inclusion Criteria4
- Age ≥18 years; AND
- HIV infection with CD4 count \< 200 cells/uL; AND
- Probable or confirmed mpox (does NOT need to be a new diagnosis); AND
- Hospitalized while symptomatic from mpox, for reasons other than (or in addition to) infection prevention and control
Exclusion Criteria2
- Inability of the individual or appropriate proxy to provide informed consent.
- In the judgment of the clinical treating team, has a medical condition or other factor that might affect their ability to participate in the evaluation.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06045923
Related Trials
A Randomized Clinical Trial to Evaluate Solutions for the Management of Virologic Failure on TLD in Sub-Saharan Africa
NCT053737583 locations
A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)
NCT0720254662 locations
First Time in Human Study of Long Acting VH4524184 Formulations
NCT063105512 locations
Development and Evaluation of a Virtual Reality Tool for At-Risk Trauma-Exposed Young People
NCT058160831 location
A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1
NCT0669480589 locations